Finance

Lists
603087:SHA
Gan & Lee Pharmaceuticals
CN¥69.81
+0.45%
(+0.31) 1D
Oct 16, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603087...
Open
CN¥70.25
High
CN¥73.00
Low
CN¥68.91
Mkt. cap
43.02B
Avg. vol.
7.43M
Volume
9.10M
Dividend
1.43%
Quarterly dividend
CN¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
36.07
52-wk high
CN¥79.99
52-wk low
CN¥51.51
EPS
CN¥1.94
No. of employees
5K
Open
CN¥70.25
High
CN¥73.00
Low
CN¥68.91
Mkt. cap
43.02B
Avg. vol.
7.43M
Volume
9.10M
Dividend
1.43%
Quarterly dividend
CN¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
36.07
52-wk high
CN¥79.99
52-wk low
CN¥51.51
EPS
CN¥1.94
No. of employees
5K
News stories
From web sources and news partners
About Gan & Lee Pharmaceuticals
CEO-
Employees5.31K
FoundedJun 17, 1998
Headquarters-
SectorBiotechnology
Websiteganlee.com.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
980.24M
1.01B
878.11M
1.34B
Cost of goods sold
234.89M
259.72M
223.40M
359.10M
Cost of revenue
234.89M
259.72M
223.40M
359.10M
Research and development expenses
143.34M
239.11M
128.04M
170.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
384.60M
444.21M
327.25M
377.07M
Operating expense
527.76M
709.00M
462.53M
557.24M
Total operating expenses
762.65M
968.72M
685.94M
916.35M
Operating income
217.59M
36.39M
192.17M
428.57M
Other non operating income
56.64M
-70.56M
-1.12M
3.22M
EBT including unusual items
234.69M
304.10M
212.64M
474.46M
EBT excluding unusual items
290.23M
257.75M
205.87M
465.75M
Income tax expense
20.03M
-21.15M
20.18M
57.59M
Effective tax rate
8.53%
-6.95%
9.49%
12.14%
Other operating expenses
-209.47K
25.46M
7.75M
9.04M
Net income
214.66M
325.24M
192.49M
417.29M
Net profit margin
21.90%
32.36%
21.92%
31.03%
Earnings per share
-
-
-
-
Interest and investment income
16.11M
303.56M
14.82M
55.17M
Interest expense
-
-231.14K
-
-102.21K
Net interest expenses
16.11M
303.33M
14.82M
55.07M
Depreciation and amortization charges
-
-
-
-
EBITDA
280.34M
110.65M
266.44M
519.60M
Gain or loss from assets sale
-
-3.71M
-
54.15K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps